Shots:

• Pfizer and Sangamo report follow-up data from the P-I/II Alta study assessing giroctocogene fitelparvovec (SB-525- or PF-07055480) in 11 patients aged 18-47yrs. with severe hemophilia A
• 5 patients with severe hemophilia A who received the 3e13 vg/kg dose showed sustained factor VIII (FVIII) activity levels- with a median of 64.2% via chromogenic assay as long as 61 wks. post-treatment. No patients experienced bleeding events or required FVIII infusions
• The P-III study of the therapy is ongoing- for which the company is anticipating the first dosing of a patient in H2’20. The therapy has received the US FDA’s ODD- RMAT and EMA’s ODD

Click here to read full press release/ article | Ref: Buinesswire | Image: WSJ